SCHEMBL2365770

SCHEMBL2365770

COc1cc2c(cc1-c1cccs1)C(C)(C(=O)C(F)(F)F)CNCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 5/20 0.37
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC6A9 P48067 2/20 0.35
ERN1 O75460 1/20 0.34
KCNK3 O14649 1/20 0.34
MAPT P10636 3/20 0.34
TUBB4A P04350 1/20 0.34
TUBB P07437 1/20 0.34
TUBA3C P0DPH7 1/20 0.34
TUBA1B P68363 1/20 0.34
TUBA4A P68366 1/20 0.34
TUBB4B P68371 1/20 0.34
TUBB3 Q13509 1/20 0.34
TUBB2A Q13885 1/20 0.34
TUBB8 Q3ZCM7 1/20 0.34
TUBA3E Q6PEY2 1/20 0.34
TUBA1A Q71U36 1/20 0.34
TUBA1C Q9BQE3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6532681 0.81 HTR2C (0.49) HTR2AHTR2CHTR2B
SCHEMBL2365641 0.79 HTR2A (0.43) HTR2AHTR2CHTR2B
SCHEMBL6631310 0.77 FGFR4 (0.35) MAPTKDM4EALDH1A1HTR2AHTR2C
SCHEMBL12295748 0.75 HTR2A (0.53) TNFRSF1ATSHRMAPK1HSD17B10ERN1
SCHEMBL2365631 0.71 DRD2 (0.40) HSD17B10MAPTKDM4EALDH1A1HPGD
SCHEMBL2477900 0.71 HTR2A (0.58) HTR2AHTR2CHTR2B
SCHEMBL2365900 0.70 HTR2A (0.51) HTR2AHTR2C
SCHEMBL6653153 0.70 HTR2C (0.38) HTR2AHTR2C
SCHEMBL6650634 0.69 ALDH1A1 (0.39) HSD17B10MAPTKDM4EALDH1A1HPGD
SCHEMBL1094195 0.69 GAA (0.43) MAPK1SLC6A9KCNK3MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2363394-A1 8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its salts, solvates or hydrates and its use for the treatment of CNS disorders Arena Pharmaceuticals, Inc. (US) 2011-09-07 EP disclosed